Constitutes a minor portion of all pediatric malignancies.
Has a low rate of event free survival and a high incidence of relapse when treated with traditional cytotoxic chemotherapy.
Incidence in children younger than 15 years seven per 1 million.
Accounts for one fourth of cases of pediatric acute leukemia.
Recent trials have achieved five year event-free survival rates ranging from 49-63%, with a relapse rate of 30%.
Outcomes in children with high risk features are significantly inferior to outcomes in children with favorable risk disease despite increased intensification of therapy, and HSCT.